



Home : [Who we are](#) : [What we do](#) : [Facilities](#) : [History](#) : [Key People](#) : [News](#) : [Research Articles](#) : [Volunteers](#) : [Employment](#) : [Contact Us](#) :

What's New?

Who We Are...

Pharmaceutical Profiles is a unique Phase 0 / I / IIa CRO which provides novel solutions in early clinical development. Since its inception in 1990, Pharmaceutical Profiles' mission has been to improve the decision-making process by offering innovative services that help select the right molecules and deselect the wrong ones in early drug development.

Pharmaceutical Profiles was founded in 1990 as a spin-out company from the University of Nottingham, UK, and the Royal Free Hospital, London, UK. The co-founders of the company were Professor S S (Bob) Davis, Dr Ian R Wilding and Dr Stephen P Newman. All founders still have a close association with Pharmaceutical Profiles Group.

Pharmaceutical Profiles is headquartered in [Ruddington](#), near Nottingham, UK, in a state-of-the-art, purpose-built facility containing a clinical research facility, GMP manufacturing [facilities](#) and research laboratories. Pharmaceutical Profiles also has representative offices in [Princeton](#), New Jersey, USA, and Tokyo, Japan.



Dr. Paul J. Clewlow

Paul is Business Development Director of Pharmaceutical Profiles.

He graduated from the University of Leicester in 1981 with a 2(i) honours degree in chemistry. He then undertook research into the synthesis and structure of petroporphyrins at University College Cardiff and the BP Research Centre, Sunbury-on-Thames, gaining his PhD in 1984. Following 4 years post-doctoral research at the Cancer Research Institute, Arizona State University in Tempe, AZ, USA and the Eidgenössische Technische Hochschule (ETH), Zürich, Switzerland, he returned to the UK in 1989 and joined Exxon Chemical.

With Exxon, he held a succession of research and technical sales positions, with increasing responsibility, eventually handling Diversification / New Business Development for Exxon Chemical Energy Chemicals Technology within the International Region. In 1994, he took up the position of Business Development Manager with Ultrafine Chemicals in Manchester, UK, a fine chemical company undertaking custom synthesis and contract R & D.

In 1996, he joined Medeval, a Phase I/IIa Clinical Research Organisation located in Manchester, UK as Business Development Manager. In March 2000, he became Head of Business Development, with world-wide responsibility for business development efforts for clinical pharmacology studies, bioanalysis, clinical pathology and pharmacokinetics / data management. He joined the board of Pharmaceutical Profiles in January 2001.

Mr. Steve Matheson

Steve is Vice President, Business Development for Pharmaceutical Profiles Inc, in North America.

A graduate of the University of St. Andrews, Steve gained valuable technical experience working for Rhone-Poulenc Rorer and latterly Merck Sharp and Dohme in Pre-clinical Drug Development.

In 1997, Steve joined Quintiles Ltd, in the UK as a field-based Business Development Executive promoting Quintiles Bioanalysis and Pharmacokinetics services out of their facilities in Edinburgh. He progressed to become Director of Preclinical Business Development in Europe with responsibility for the sales and marketing of Early Development services. In 2002, Steve was appointed Senior Director of Business Development for Quintiles in Kansas City, Missouri, USA.

Steve is responsible for the promotion of Pharmaceutical Profiles' services in the USA and Canada.

Consultants

Dr. Ian Wilding

Dr Ian Wilding is currently a Scientific Advisor at Pharmaceutical Profiles, an early phase development company focused on improving decision making in early drug development by using human absorption studies and product visualization investigations in man.

He received his first class honours degree in Pharmacy from the University of Nottingham in 1984 and his PhD from the same University in 1990. Dr Wilding has published over 230 research papers/abstracts and has supervised a number of PhD students in the area of Biopharmaceutics at Nottingham University. In addition, he is a special Professor in the Institute of Pharmaceutical Sciences at Nottingham University. Dr Wilding is a frequent speaker at International meetings and is a respected authority on drug delivery and intestinal absorption. In 1997 he served as an expert scientist for the FDA in the area of Food Effects on Drug Bioavailability and is currently the only non-American scientist working with PQRI examining US regulatory guidance in the area of Oral Biopharmaceutics.

Dr Wilding also holds the following positions:

- Member of the UK's CBI Technology and Innovation Committee
- Director of BioCity Nottingham, the largest bioscience incubator in Europe.

Professor S S (Bob) Davis

Bob is a founder of Pharmaceutical Profiles and a consultant to the company.

Bob Davis obtained his Bachelors degree in Pharmacy from the School of Pharmacy at the University of London in 1964.

He remained at the same University to study for a PhD in colloid science (1967). In 1968 he was awarded a one year Fulbright Scholarship to undertake postdoctoral studies with Professor Takeru Higuchi at the University of Kansas in the field of solution thermodynamics. In 1970 he moved to the University of Aston in Birmingham as senior lecturer and head of the Pharmaceutics section. Here, he built up an active research group focussing on drug delivery systems.

Bob took up his present position at Nottingham in 1975. Since then, he has run a large research group, studying novel drug delivery systems. Topics of research have included drug targeting (colloidal carriers), transmucosal delivery, oral and parenteral systems for controlled release and product evaluation through gamma scintigraphy. He has published more than seven hundred papers and is the co-editor of seven books.

He is also credited with founding two commercial pharmaceutical organisations, Danbiosyst (UK) Ltd (now part of West Pharmaceutical Services) and Pharmaceutical Profiles Limited.

Dr. Stephen Newman

Stephen is a Scientific Advisor to Pharmaceutical Profiles.

Stephen was a Medical Physicist at the Royal Free Hospital between 1971 and 1982 and was a Principal Physicist and Honorary Senior Lecturer in the Department of Thoracic Medicine, Royal Free Hospital and School of Medicine from 1982 to 1991.

He is acknowledged as a leading expert in inhalation drug delivery. He advises many companies on the challenges and opportunities for nasal and pulmonary drug delivery for both treatment of respiratory disease and systemic drug delivery.

He is also widely accepted as the leading light in the introduction of gamma scintigraphy as an imaging technique to assess lung deposition of inhalation devices.

